SCHEMBL6479531

SCHEMBL6479531

CCCS(=O)(=O)NC[C@H](C)Oc1ccc(-c2cccc(NS(C)(=O)=O)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.46
KDM1A O60341 1/20 0.42
GRIA2 P42262 5/20 0.42
KCNH2 Q12809 3/20 0.42
BRD4 O60885 2/20 0.41
TDP2 O95551 2/20 0.40
NR3C2 P08235 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
FYN P06241 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474298 1.00 KIF11 (0.46) KIF11KDM1AGRIA2KCNH2BRD4
SCHEMBL6481826 1.00 KIF11 (0.46) KIF11KDM1AGRIA2KCNH2BRD4
SCHEMBL6481819 0.94 SMN1; SMN2 (0.44) GRIA2BRD4SMN1; SMN2MEN1KMT2A
SCHEMBL6481822 0.86 GRIA2 (0.51) KIF11KDM1AGRIA2KCNH2BRD4
SCHEMBL6474292 0.86 GRIA2 (0.51) KIF11KDM1AGRIA2KCNH2BRD4
SCHEMBL6474904 0.86 GRIA2 (0.51) KIF11KDM1AGRIA2KCNH2BRD4
SCHEMBL6474047 0.84 PPARG (0.44) SMN1; SMN2KMT2AGRIA4
SCHEMBL6475297 0.84 GRIA4 (0.48) SMN1; SMN2CYP1A2CYP2C19GRIA4
SCHEMBL6482324 0.84 GRIA4 (0.46) CYP1A2TSHRCYP2C19GRIA4
SCHEMBL6479543 0.84 GRIA4 (0.45) GRIA4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 KIF11 4340/4885KDM1A 2552/4885GRIA2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.